Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.255 SEK
−109.29 M SEK
0.00 SEK
90.76 M
About ASCELIA PHARMA AB
Sector
CEO
Magnus Olafsson Corfitzen
Headquarters
Malmö
Website
Founded
1999
ISIN
SE0010573113
FIGI
BBG00NF05BL9
Ascelia Pharma AB engages in the research and development of pharmaceutical products for the treatment of cancer and cancer-related diseases. It offers the following clinical stage product candidates: Mangoral, a liver imaging drug being developed for detection and localization of potential liver metastases; and Oncoral, a tablet-based formulation of the chemotherapeutic agent irinotecan, intended for the treatment of advanced gastric cancer. The company was founded on May 17, 1999, and is headquartered in Malmö, Sweden.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ACE is 3.060 SEK — it has increased by 2.00% in the past 24 hours. Watch ASCELIA PHARMA AB stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange ASCELIA PHARMA AB stocks are traded under the ticker ACE.
ACE stock has fallen by −11.30% compared to the previous week, the month change is a 15.69% rise, over the last year ASCELIA PHARMA AB has showed a −20.52% decrease.
We've gathered analysts' opinions on ASCELIA PHARMA AB future price: according to them, ACE price has a max estimate of 10.00 SEK and a min estimate of 10.00 SEK. Watch ACE chart and read a more detailed ASCELIA PHARMA AB stock forecast: see what analysts think of ASCELIA PHARMA AB and suggest that you do with its stocks.
ACE stock is 5.66% volatile and has beta coefficient of 0.04. Track ASCELIA PHARMA AB stock price on the chart and check out the list of the most volatile stocks — is ASCELIA PHARMA AB there?
Today ASCELIA PHARMA AB has the market capitalization of 294.08 M, it has increased by 2.22% over the last week.
Yes, you can track ASCELIA PHARMA AB financials in yearly and quarterly reports right on TradingView.
ASCELIA PHARMA AB is going to release the next earnings report on Feb 7, 2025. Keep track of upcoming events with our Earnings Calendar.
ACE earnings for the last quarter are −0.14 SEK per share, whereas the estimation was −0.14 SEK resulting in a 0.00% surprise. The estimated earnings for the next quarter are −0.14 SEK per share. See more details about ASCELIA PHARMA AB earnings.
ASCELIA PHARMA AB revenue for the last quarter amounts to 0.00 SEK, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ACE net income for the last quarter is −21.73 M SEK, while the quarter before that showed −13.27 M SEK of net income which accounts for −63.76% change. Track more ASCELIA PHARMA AB financial stats to get the full picture.
No, ACE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 13.00 employees. See our rating of the largest employees — is ASCELIA PHARMA AB on this list?
Like other stocks, ACE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ASCELIA PHARMA AB stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ASCELIA PHARMA AB technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ASCELIA PHARMA AB stock shows the sell signal. See more of ASCELIA PHARMA AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.